Sophia Genetics SA (NAS:SOPH)

Q4 2024 Sophia Genetics SA Earnings Call Transcript

Mar 4, 2025 / 01:00 PM GMT

Release Date Price: $3.1 (-13.17%)

Transcript

Key Points

Positve

Sophia Genetics SA (SOPH) signed a record 92 new core genomic customers in 2024, including 31 in Q4, indicating strong market demand.
The company achieved a 13% year-over-year growth in clinical analysis volume, excluding COVID-related impacts.
Sophia Genetics SA (SOPH) expanded its global reach to nearly 800 healthcare institutions across more than 70 countries.
The launch of new applications, MSK Access and MSK Impact, has been well-received, with 34 customers adopting MSK Access across 20 countries.
The company improved its adjusted operating loss by 20% year-over-year, demonstrating effective cost management and operational efficiency.

Negative

Biopharma revenue declined by approximately $4 million in 2024, impacting overall revenue performance.
Gross margin decreased from 69% in 2023 to 67% in 2024, indicating pressure on profitability.
The company experienced a decline in hereditary cancer application growth as labs shifted to exome applications.
Latin America saw a notable decline in performance due to the acquisition of a top customer by another lab.
Sophia Genetics SA (SOPH) anticipates a moderate negative impact from exchange rate volatility in 2025.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SOPH.OQ - Sophia Genetics SA
Q4 2024 Sophia Genetics SA Earnings Call
Mar 04, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Morning. My name is Lee Wei, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Sofia Genetics 4th quarter and full year 2024 earnings conference call.

At this time all lines are in a listen-only mode. Following the presentation we will conduct a question and answer session.

If at any time during this call you require immediate assistance, please press 0 for the operator.

This call is being recorded on Tuesday, March 4, 2025.

I would not like to turn the conference over to Kelly Saner, Sophia Genetics, head of strategy and industrial relations. You may begin.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.